Inclusion Criteria

Inclusion Criteria at time of Procurement

Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's
Lymphoma, (regardless of the histological subtype) or EBV
(associated)-T/NK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV)

In second or subsequent relapse (or first relapse or with active disease if
immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission
who have a high risk of relapse) OR any patient with primary disease or in first remission
if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin
disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a
Richter's transformation of CLL. (Group A)

OR

In remission or with minimal residual disease status after autologous or syngeneic stem
cell transplantation (SCT). (Group B)

- EBV positive tumor

- Weighs at least 12kg

- Informed consent explained to, understood by and signed by patient/guardian.
Patient/guardian given copy of informed consent.

Inclusion Criteria at time of Infusion

Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's
Lymphoma (regardless of histologic subtype), or EBV (associated)-T/NK-lymphoproliferative
disease or Severe Chronic Active EBV (CAEBV) and

In second or subsequent relapse (or first relapse or with active disease if
immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission
who have a high risk of relapse) OR any patient with primary disease or in first remission
if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin
disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a
Richter's transformation of CLL. (Group A)

OR

In remission or with minimal residual disease status after autologous or syngeneic SCT.
(Group B)

- EBV positive tumor (can be pending at this time)

- Patients with life expectancy > 6 weeks.

- Patients with bilirubin < 3x upper limit of normal, AST < 5x upper limit of normal,
and Hgb > 8.0 (may be a transfused value).

- Patients with a creatinine < 2x upper limit of normal for age

- Pulse oximetry of > 90% on room air

- Patients should have been off other investigational therapy for 4 weeks prior to
entry in this study.

- Patients with a Karnofsky/Lansky score of > 50

- Sexually active patients must be willing to utilize one of the more effective birth
control methods during the study and for 6 months after the study is concluded. The
male partner should use a condom.

- Informed consent explained to, understood and signed by patient/guardian.
Patient/guardian given copy of informed consent.

- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (> 4000
genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV

Exclusion Criteria at Time of Procurement

- Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)

Exclusion Criteria at Time of Infusion

- Pregnant or lactating

- Severe intercurrent infection.

- Current use of systemic corticosteroids > 0.5 mg/kg/day